Experts involved in the Deal:
Corporate Law, Mergers & Acquisitions:
- Bob Calmes
- Caroline Koepp
- Solenne Fratta
- Dana Yessimova
- Ivan Ganchev
Tax:
- Jan Neugebauer
- Rafael Lourenço
- Yasmine El Harsal
Arendt & Medernach advised Procaps Group, S.A. (“Procaps” or the “Company”), a leading Latin America integrated pharmaceutical and healthcare company, in connection with a landmark transaction involving a successful USD 130 million equity raise and a comprehensive restructuring of existing debt with the Company’s key lenders (the “Restructuring”), marking a major milestone in Procaps’ multi-phase transformation strategy, focused on growth and enhanced corporate governance.
The equity raise comprised a USD 90 million private placement of ordinary shares of Procaps to the benefit of seasoned investors with deep expertise in the healthcare and pharmaceutical sectors, the issuance of USD 40 million in secured convertible notes to certain of such strategic investors and the conversion of such notes into ordinary shares of Procaps. As part of the comprehensive Restructuring, certain of the new equity investors have formally assumed the leadership of the Company, bringing a renewed focus on operational excellence, financial discipline and long-term value creation.
The debt restructuring encompassed moreover significant negotiations with the Company’s key financial stakeholders and included approximately USD 209 million of debt previously subject to forbearance, designed to support long-term sustainability and cash flow flexibility.
These pivotal developments on both the equity and debt side are expected to reinforce Procaps’ financial health, improve its operational performance, and position Procaps for sustainable long-term growth under a redesigned leadership and organizational structure.
Arendt & Medernach provided comprehensive legal support to Procaps across the strategic, financial, and operational components of the Restructuring.
This engagement reflects Arendt & Medernach’s continued commitment to supporting transformational cross-border transactions and high-impact restructuring projects, reinforcing its position as a trusted advisor to major international clients in the pharmaceutical and healthcare sectors.